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Parkinsonism and Related Disorders 20 (2014) 584e589Contents lists avaiEditor’s comment: It is widely believed that genetic mechanisms leading to increased brain levels of a-synuclein (SNCA) in the brain are
associated with an increased risk of developing Parkinson’s disease (PD). In this article, Markopoulou and colleagues report on their genetic
evaluation of over 1000 well characterized PD patients with results that challenge the notion that increased expression of SNCA is uni-
formly harmful. Surprisingly, they ﬁnd that the same genotypes of the SNCA-promoting gene REP-1 that are known to be associated
with increased levels of SNCA and an increased risk of developing PD are also associated with better motor and cognitive outcomes in
patients in whom the clinical symptoms of the disorder are already present. These ﬁndings suggest that a-synuclein’s role in the patho-
genesis of PD may be more complex than once thought. From a practical perspective these results may introduce important new consid-
erations in our quest to develop effective neuroprotective therapies for patients in different clinical stages of this disorder.
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a-Synuclein gene (SNCA) multiplications cause familial parkinsonism and allele-length polymorphisms
within the SNCA dinucleotide repeat REP1 increase the risk for developing Parkinson’s disease (PD). Since
SNCA multiplications increase SNCA expression, and REP1 genotypes that increase the risk of developing
PD show increased SNCA expression in cell-culture systems, animal models, and human blood and brain,
PD therapies seek to reduce SNCA expression. We conducted an observational study of 1098 PD cases to
test the hypothesis that REP1 genotypes correlated with reduced SNCA expression are associated with
better motor and cognitive outcomes. We evaluated the association of REP1 genotypes with survival free
of Hoehn and Yahr stages 4 or 5 (motor outcome) and of Modiﬁed Telephone Interview for Cognitive
Status score 27 or Alzheimer’s Disease Dementia Screening Interview score 2 (cognitive outcome).
Median disease duration at baseline was 3.3 years and median lag time from baseline to follow-up was
7.8 years. Paradoxically, REP1 genotypes associated with increased risk of developing PD and increased
SNCA expression were associated with better motor (HR ¼ 0.87, p ¼ 0.046, covariate-adjusted age-scale
analysis; HR ¼ 0.85, p ¼ 0.020, covariate-adjusted time-scale analysis) and cognitive outcomes
(HR ¼ 0.90, p ¼ 0.12, covariate-adjusted age-scale analysis; HR ¼ 0.85, p ¼ 0.023, covariate-adjusted time-
scale analysis). Our ﬁndings raise the possibility that SNCA has a dual, opposing, and time-dependent role.
This may have implications for the development of therapies that target SNCA expression.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).tia Screening Interview; bp, base pair; H&Y, Hoehn and Yahr; HR, hazard ratio; LD, linkage disequilibrium; MEPD,
, Mini Mental State Examination; PD, Parkinson’s disease; SNCA, a-synuclein gene; SNP, single-nucleotide polymorphism;
atus; UPDRS, Uniﬁed Parkinson’s Disease Rating Scale.
an, Department of Neurology, NorthShore University Health System, 2650 Ridge Avenue, Evanston, IL 60201, USA.
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K. Markopoulou et al. / Parkinsonism and Related Disorders 20 (2014) 584e589 5851. Introduction walk without assistance?” Both questions were appropriately reworded for proxy
interviews.a-Synuclein gene (SNCA) multiplications cause familial parkin-
sonism via an overexpression mechanism [1]. Parkinson’s disease
(PD) susceptibility is inﬂuenced by allele-length polymorphisms in
the mixed dinucleotide repeat REP1 (D4S3481,w10 kb upstream of
the SNCA transcription start site) [2], which are correlated with
altered SNCA expression in cell cultures [3], transgenic mouse brain
[4], and human blood and brain [5,6]. Speciﬁcally, longer REP1
allele lengths (263 bp) that correlate with increased SNCA expres-
sion are associated with increased risk of developing PD and
shorter REP1 allele lengths (259 bp) that correlate with reduced
SNCA expression are associated with reduced risk of developing PD
[2]. These genetic ﬁndings, together with a-synuclein immuno-
staining of Lewy bodies [7], provide proof of principle for therapies
aiming to reduce SNCA expression in PD [8,9].
Recently, Ritz et al. [10] reported the association of SNCA REP1
263 bp alleles (correlated with increased expression) with more
rapid motor symptoms progression in PD as assessed by the rate of
decline of Uniﬁed Parkinson’s Disease Rating Scale (UPDRS) motor
scores over a 5-year interval. They interpreted their ﬁndings to
support therapies targeting reduction of SNCA expression in PD.
Here we present a study of the association of twenty SNCA variants
(REP1 and 19 additional haplotype-tagging SNPs) and survival free
of motor and cognitive outcomes, for 1098 PD subjects with up to
13 years of follow-up. Since increased SNCA expression is associated
with increased risk of developing PD, we hypothesized that REP1
genotypes correlated with reduced SNCA expression (one or two
259 bp alleles) would be associated with greater survival free of
developing motor and cognitive outcomes in PD. Surprisingly, the
ﬁndings of our studies are opposite to this hypothesis and contrast
with those of Ritz et al. and suggest a possible time-dependent,
dual and opposing effect of SNCA in PD.
2. Materials and methods
2.1. Subjects
Clinical information and biological samples were collected with written
informed consent following a protocol approved by the Mayo Clinic IRB (Rochester,
MN). Study subjects were 1098 PD cases from the Molecular Epidemiology of Par-
kinson’s Disease study (“MEPD study”, NIH 2R01ES10751) referred sequentially to
the Department of Neurology of the Mayo Clinic in Rochester, MN, from June 1, 1996
through June 30, 2007. They resided in Minnesota or a neighboring state. All PD
cases were examined in a standardized fashion by neurologists specializing in
Movement Disorders, and employing a comprehensive protocol for clinical assess-
ment. Cases fulﬁlled criteria for clinically deﬁnite or probable PD [11].
2.2. Molecular analyses
Blood was collected and genomic DNAwas obtained. Allele length of SNCA REP1
was assessed using an Applied Biosystems sequencing platform (Genotyping Shared
Resources, Mayo Clinic, Rochester, MN) and 19 haplotype-tagging SNCA SNPs were
assessed using an Illumina GoldenGate genotyping platform [12].
2.3. Outcome measurements
Motor and cognitive outcome data for 1098 PD cases were collected by tele-
phone interview questionnaires directly with the cases or via proxy when inca-
pacitated or deceased. The direct interview questionnaire included the Telephone
Interview of Cognitive Status-Modiﬁed (TICS-M) [13] and questions regarding motor
milestones such as inability to stand or walk unassisted (and dates). The proxy
questionnaires collected the same information, with the exception of screening for
dementia using the Alzheimer’s Disease Dementia Screening Interview (AD-8) [14]
because AD-8 is a brief informant-based measure that reliably differentiates be-
tween non-demented and demented individuals and is sensitive to the earliest signs
of cognitive change as reported by a proxy informant.
The motor outcome was deﬁned as Hoehn and Yahr (H&Y) stage 4 or 5 and
assessed at baseline via clinical assessment and imputed at follow-up via tele-
phone interview. The question asked at the telephone interview was: “Are you
able to stand or walk without someone else helping you, or without a cane or
walker?” A “no” response corresponded to H&Y stages 4 or 5. A “no” response
was followed by the question: “At what age were you no longer able to stand orCognitive outcome was assessed at baseline using the Mini Mental State Ex-
amination (MMSE). The cognitive outcome was deﬁned as MMSE <26 [15].
Cognitive outcome at follow-up was assessed via telephone interview using the
TICS-M (direct interviews) or the AD-8 (proxy interviews). Cognitive outcome was
deﬁned as a TICS-M score 27 or AD-8 score 2. The outcome assessments were
identical to those that we reported for a genome-wide association study (GWAS) of
motor and cognitive outcomes in PD [16]. That study did not include SNCA-REP1
genotypes and the 19 SNCA haplotype-tagging SNPs that are the focus of this study,
and that study included only a subset (n ¼ 443) of the cases included in this study
(n ¼ 1098).
2.4. Statistical analyses
Statistical analyses evaluated the association of each genetic variant with motor
and cognitive impairment, with the primary outcome being time-to-event (motor or
cognitive outcomes). Cox proportional hazards regression models were used to
assess the association of outcomes with genotypes. For cases with no evidence of
motor or cognitive outcomes, time-to-censoring was deﬁned as the time between
the baseline clinical assessment and the telephone interview, or time between
baseline and death if the individual was deceased. For cases with evidence of motor
or cognitive outcomes, time-to-eventwas deﬁned based on the age of onset of motor
or cognitive outcomes as determined by direct or proxy telephone interviews.
Subjects with H&Y stage 4/5 or with MMSE<26 at baseline, were excluded from the
respective motor or cognitive outcomes survival analyses. To limit survival bias, age
at enrollment was considered as time 0 (or baseline). Analyses were performed both
using the age-scale and the time-on-study scale. While the time-on-study scale is
often used in analyses of disease progression, analysis on the age scale is more
appropriate when studying outcomes associated with age in an aging population
[18]. Log-rank tests were used to determine signiﬁcance and associations between
outcomes and genetic variables using hazard ratios (HR) with 95% conﬁdence in-
tervals. KaplaneMeier plots were used to visualize the overall survival function, and
stratiﬁed by genetic variables.
Prior to testing the effects of SNCA variants on motor and cognitive impairment
outcomes, analyses were performed to identify relevant covariates associated with
the outcomes. Relevant covariates were then included in the Cox proportional
hazards models that were used to assess the association of outcomes with geno-
types. The age-scale analysis of the motor impairment outcome included sex, dis-
ease duration at baseline, and L-DOPA treatment at baseline as covariates, while the
cognitive impairment analysis included sex, disease duration at baseline, and edu-
cation as covariates. The age-scale analyses of motor and cognitive outcomes were
also performed without covariate adjustment. Similarly, the analyses on the time-
on-study scale were performed without and with covariate adjustment (the same
covariates as above with the addition of age at enrollment as a covariate in analyses
of both motor and cognitive outcomes).
The primary analysis included the association of outcomes with SNCA REP1
genotypes using the REP1 score as described previously [17]. The REP1 score ranged
from 0 (lowest PD risk, lowest SNCA expression) to 4 (highest PD risk, highest SNCA
expression). Secondary analyses investigated the association of motor and cognitive
outcomes with 19 haplotype-tagging SNCA SNPs deﬁned by the minor allele count
(0, 1, or 2 copies of the minor frequency allele); and with REP1 genotypes re-deﬁned
by minor allele counts (0, 1, or 2 copies of the 259 bp allele; or 0, 1, or 2 copies of the
263 bp allele). As SNCA REP1 was the genetic polymorphism of interest, primary
analyses were not corrected for multiple comparisons. The Bonferroni correction for
multiple comparisons was applied to the secondary analyses (20 tests for each
outcome). Results with uncorrected p-values <0.05 in the primary analyses or
Bonferroni-corrected p-values <0.05 in the secondary analyses were considered
signiﬁcant.
The statistical packages SAS (version 9.2; SAS Institute Inc., Cary, NC) and R
(version 2.14; R Development Core Team (2011). R: A language and environment for
statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN
3-900051-07-0, URL http://www.R-project.org/) were used for all analyses.
3. Results
3.1. Demographic and clinical characteristics
1098 MEPD cases were included in this study (Supplemental
Table 1). 85 cases were lost to follow-up, and 91 PD cases (or
proxies) refused follow-up interviews. Thus, the overall participa-
tion rate among those contacted was 91.0%. At follow-up, 467 direct
interviews, 180 proxy interviews for incapacitated subjects, and
275 proxy interviews for deceased subjects were performed. From
the 922 participating cases 604 were men (65.5%) and 318 women
(34.5%) primarily of Caucasian race and European ancestry. Median
Fig. 1. Kaplan Meier plot for SNCA REP1 and survival free of motor impairment
(H&Y stages 4 or 5). The genotype 259 bp/259 bp corresponds to REP1 score ¼ 0, and
259 bp/261 bp to REP1 score ¼ 1, and 261 bp/261 bp or 259 bp/263 bp to REP1
score ¼ 2, and 261 bp/263 bp to REP1 score ¼ 3, and 263 bp/263 bp to REP1 score ¼ 4.
A corresponds to the covariate unadjusted, age-scale analysis (HR ¼ 0.87, 95% CI 0.75e
0.99, p ¼ 0.042); and B corresponds to the covariate unadjusted, time-on-study
analysis (HR ¼ 0.81, 95% CI 0.70e0.93, p ¼ 0.0035).
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pating cases (70.7%) had been treated with levodopa at baseline. 62
cases (6.7%) that had reached H&Y stages 4/5 at baseline were
removed from the motor outcomes analyses. 59 cases (6.4%) that
had reached MMSE <26 at baseline were removed from the
cognitive analyses.
The median lag time from baseline to follow-up was 7.8 years
(range 3.3e13 years). 44 cases with a TICS-M score 27 were
interviewed directly and repeated interviews (proxy for incapaci-
tated subjects) were conducted in order to obtain valid dates and
other information for the survival analyses. Information regarding
levodopa therapy at follow-up or cumulative dose exposures was
not available.
3.2. Molecular analysis
Twenty SNCA variants were genotyped and their positions
are shown in a Linkage Disequilibrium (LD) map for SNCA
(Supplemental Fig. 1).
3.3. REP1 and motor outcomes
Our initial hypothesis was that PD cases with lower REP1 scores,
associated with reduced PD risk and correlated with reduced SNCA
expression, would have reduced risk of developing motor and/or
cognitive impairment and thus longer survival free of these out-
comes. However, we observed the opposite association: PD cases
with higher REP1 scores had reduced risk of developing motor
impairment and longer survival free of the outcome. This result was
statistically signiﬁcant both in the unadjusted and the covariate-
adjusted analyses on the time-on-study scale as well as the unad-
justed and covariate-adjusted analyses performed on the age-scale
(adjusted analysis on age-scale: HR ¼ 0.87, 95% CI 0.75e1.00,
p¼ 0.046; see Supplemental Table 2). Under the covariate-adjusted
age-scale model, having a lower REP1 score conferred a nearly two-
fold greater risk for developing the motor outcome than a higher
REP1 score (HR ¼ 1.78, 95% CI 1.01e3.15, REP1 score of 0 vs. REP1
score of 4). Fig. 1 shows the KaplaneMeier plot for survival free of
developing the motor outcome by the REP1 score. Genotype and
allele frequencies are shown in Table 1.
3.4. REP1 and cognitive outcomes
Consistent with our ﬁndings for motor outcomes, we observed
an opposite-than-expected association for cognitive outcomes. PD
cases with higher REP1 scores had reduced risk of developing
cognitive impairment and longer survival free of the outcomes.
While this result was statistically signiﬁcant in the unadjusted and
covariate-adjusted analysis on the time scale (adjusted analysis on
time-scale: HR ¼ 0.85, 95% CI 0.75e0.98, p ¼ 0.023), it just failed to
achieve signiﬁcance (p ¼ 0.058) in the unadjusted analysis on the
age-scale, and was not signiﬁcant in the covariate-adjusted analysis
on the age-scale (p ¼ 0.12). Under the covariate-adjusted age-scale
model, having a low REP1 score conferred a 1.5 times greater risk
for developing the cognitive outcome than having a high REP1
score (HR¼ 1.53, 95% CI 0.90e2.60, REP1 score of 0 vs. REP1 score of
4). Results of all analyses are shown in Supplemental Table 3. Fig. 2
shows the KaplaneMeier plots for survival free of the cognitive
outcome by REP1 score. Genotype and allele frequencies are shown
in Table 2.
3.5. SNPs and motor and cognitive outcomes
The association results for all genotyped SNCA variants (19 SNPs,
REP1) and developing the motor and cognitive outcomes areincluded in Supplemental Tables 2 and 3. None of the SNPs were
signiﬁcantly associated with developing motor or cognitive
impairment after Bonferroni correction for multiple testing,
including those tagging the 30 LD block.
4. Discussion
In contrast to our original hypothesis our results reveal an un-
expected association of the SNCA REP1 genotypes correlated with
Table 1
REP1 genotype frequencies for MEPD Motor outcomes (N ¼ 854).
REP1 genotypes Genotype frequency n (%)
257/261 2 (0.2%)
257/263 1 (0.1%)
259/259 49 (5.7%)
259/261 257 (30.1%)
259/263 25 (2.9%)
259/265 1 (0.1%)
261/261 422 (49.4%)
261/263 90 (10.5%)
261/265 1 (0.1%)
263/263 6 (0.7%)
REP1 score Genotype frequency n (%)
0 49 (5.8%)
1 257 (30.3%)
2 447 (52.7%)
3 90 (10.6%)
4 6 (0.7%)
REP1 259 bp Genotype frequency n (%)
0 522 (61.1%)
1 283 (33.1%)
2 49 (5.7%)
REP1 263 bp Genotype frequency n (%)
0 732 (85.7%)
1 116 (13.6%)
2 6 (0.7%)
REP1 261 bp Genotype frequency n (%)
0 82 (9.6%)
1 350 (41.0%)
2 422 (49.4%)
Fig. 2. Kaplan Meier plot for SNCA REP1 and survival free of cognitive impairment
(TICS-M score 27 or AD-8 score 2). The genotype 259 bp/259 bp corresponds to
REP1 score ¼ 0, and 259 bp/261 bp to REP1 score ¼ 1, and 261 bp/261 bp or 259 bp/
263 bp to REP1 score ¼ 2, and 261 bp/263 bp to REP1 score ¼ 3, and 263 bp/263 bp to
REP1 score ¼ 4. A corresponds to the covariate unadjusted, age-scale analysis
(HR ¼ 0.88, 95% CI 0.78e1.00, p ¼ 0.058); and B corresponds to the covariate unad-
justed, time-on-study analysis (HR ¼ 0.81, 95% CI 0.71e0.92, p ¼ 0.0017).
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and cognitive outcomes in a large and well-characterized cohort of
PD cases. Our results are inconsistent with ﬁndings from SNCA
multiplicationmutations in familial parkinsonism, where increased
SNCA genomic dosage and SNCA expression were associated with
earlier age at onset, faster progression and increased motor and
cognitive severity [1]. However, our results are consistent with
clinical and genetic information that two of the authors (KM, BAC)
newly obtained from a previously reported Greek family with PD
[19]. In affected kindred members, the SNCA c.157G>A (p.A53T)
mutation is in phase with the REP1 259-bp allele (Supplemental
Fig. 2). All affected individuals with the 259-bp REP1 allele had a
severe phenotype with poor motor and cognitive outcomes (me-
dian duration to H&Y stages 4/5 was 7 years and to dementia was 7
years), while a recombinant lacking the 259-bp REP1 allele remains
asymptomatic past the mean age of onset for their generation. This
is consistent with the hypothesis that the co-localization of the
causal gene mutation with the 259-bp REP1 allele is associated
with variable expressivity (worse outcomes) in this family.
Our results are also inconsistent with ﬁndings reported by Ritz
et al. [10], where REP1 alleles associated with increased PD risk and
correlated with increased SNCA expression were associated with
the development of worse motor outcomes. There are several
possible explanations for these conﬂicting results. First, the differ-
ence may be due to sample size. Our sample at study enrollment
was 3-fold larger than that of Ritz et al. (1098 vs. 363 PD cases), and
at follow-up was nearly 4-fold larger (854 vs. 233 PD cases). Small
and underpowered samples have greater false-positive rates and
may provide erroneous or exaggerated estimates of the direction or
size of effect. Second, the population characteristics were different.
Our study population was racially and ethnically homogeneous
with subjects of Caucasian and European descent, whereas in the
Ritz study w19% of the subjects were non-Caucasian. The fre-
quencies and effects of gene variants vary by race and ethnicity, and
population stratiﬁcation can further erode statistical power or bias
towards false-positive associations. Third, we deﬁned motoroutcome differently. Our outcome was reaching H&Y stages 4/5;
inability to stand or walk unassisted represents a major milestone
in PD progression and is therefore likely to be recalled reliably by
patients or their proxies. Ritz et al. used the rate of decline in motor
severity measured by the UPDRS part III scale. The UPDRS is subject
to treatment effects and inter-rater variability, and change in the
UPDRS score by ﬁve points may not result in a meaningful change
in H&Y stage. Our ﬁndings were internally consistent for the
development of both motor and cognitive outcomes, whereas the
Table 2
REP1 genotype frequencies in cognitive outcomes (N ¼ 858).
REP1 genotypes Genotype frequencies n (%)
257/261 2 (0.2%)
257/263 1 (0.1%)
259/259 48 (5.6%)
259/261 265 (30.9%)
259/263 25 (2.9%)
259/265 1 (0.1%)
261/261 416 (48.5%)
261/263 94 (11.0%)
261/265 1 (0.1%)
263/263 5 (0.6%)
REP1 score Genotype frequency n (%)
0 48 (5.6%)
1 265 (31.1%)
2 441 (51.7%)
3 94 (11.0%)
4 5 (0.6%)
REP1 259 bp Genotype frequency n (%)
0 519 (60.5%)
1 291 (33.9%)
2 48 (5.6%)
REP1 263 bp Genotype frequency n (%)
0 733 (85.4%)
1 120 (14.0%)
2 5 (0.6%)
REP1 261 bp Genotype frequency n (%)
0 80 (9.3%)
1 362 (42.2%)
2 416 (48.5%)
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duration was substantially longer, nearly ﬁfteen years vs. ﬁve years
of Ritz et al. It is conceivable that we are observing differential ef-
fects of REP1-allele genotypes at different disease stages.
While a cross-sectional study of SNCA polymorphisms and the
development of motor outcomes in a cohort of multiplex families
with PD has been reported, it was not representative of sporadic PD
[20]. Association studies of SNCA polymorphisms and cognitive
outcomes in sporadic PD were small, considered only a few vari-
ants, and were mostly cross-sectional [21e23].
Our genetic association study has several strengths: First, we
used an observational study design to evaluate the effects of SNCA
genotypes on the development of motor and cognitive outcomes in
PD. While there have been experimental studies of therapies tar-
geting SNCA expression in model systems [8,9], observational
studies of SNCA effects on the development of motor and cognitive
outcomes to assess the long term beneﬁts of therapeutic in-
terventions are lacking. Second, all MEPD study cases were
recruited using strict enrollment and diagnostic criteria, resided in
a deﬁned geographic region, and examined at baseline by Move-
ment Disorders specialists using a standardized and comprehen-
sive clinical assessment protocol. Third, our follow-up telephone
interview assessments included validated measures allowing us to
determine outcomes directly or by proxy for 84% of the subjects.
Fourth, follow-up interval was long (up to 13 years) and the study
had sufﬁcient power to detect clinically meaningful effects. Fifth,
genotypes were determined for REP1 but also for 19 SNCA SNPs.
Our study also has several weaknesses. First, a sampling bias
cannot be excluded as our PD cohort was referral-based. Attempts
to limit sampling bias included recruiting cases prospectively from
a deﬁned geographic region and by not excluding or enriching for
familial PD cases. The frequency of known PARK mutations was
very low [24,25]. Second, to limit survival bias we evaluated out-
comes in PD cases with variable disease duration at baseline and
included disease duration at baseline as an adjustment variable in
the statistical models. Third, the measurements at baseline andfollow-up employed different methods and the validity of self or
proxy reported assessments and imputed H&Y stages are unclear.
Fourth, treatment effects cannot be excluded since our PD cohort
was not randomized to treatment. L-DOPA therapy at baseline was
included as an adjustment variable in some of the models, but
cumulative dose exposures to dopaminergic therapy could not be
ascertained. Fifth, statistical power may be greater for repeated
quantitative measures than for singly performed dichotomous
measures and survival analyses.
Both a neurotoxic and a neuroprotective role for SNCA expres-
sion have been proposed in cell culture and animal models [26]. In
addition, both up-regulation and down-regulation of SNCA
expression in PD and control brains have been reported [6,27e29].
It is conceivable that SNCA expression variability may reﬂect a dy-
namic state of SNCA regulation over the disease course. SNCA REP1
genotypes associated with reduced expression may function in a
neuroprotective manner reducing the risk to develop PD, whereas
well after PD symptom-onset these genotypes may exacerbate
disease progression. One speculative mechanism is that after dis-
ease onset, as a-synuclein and its proteolytic fragments are
sequestered in aggregates (e.g., Lewy bodies), relatively reduced
expression fails to support the production of sufﬁcient pools of
normal a-synuclein, which in turn contributes to further disease
progression. Individuals with short REP1 alleles may be more at-
risk for this condition following disease onset. A dual and
opposing effect of gene/protein function in neurological disease is
not limited to SNCA/a-synuclein. b-Amyloid, which plays a critical
role in the pathogenesis of Alzheimer’s disease, has a beneﬁcial
effect in animal models of multiple sclerosis [30,31]. The apolipo-
protein E gene ε2 variant (APOE ε2) is associatedwith a reduced risk
for Alzheimer’s disease, but with an increased amyloid neuropa-
thology burden in Alzheimer’s disease patients older than 90 years;
and while APOE ε2 reduces the risk for Alzheimer’s disease, it in-
creases the risk for cerebral amyloid angiopathy and associated
hemorrhages (which are prevalent in Alzheimer’s disease patients)
[32]. Further, APOE ε4 alleles have differential effects on amyloid
load and glucose metabolism in the frontal and occipital cortices of
Alzheimer’s disease patients [33].
Taken together, these observations point to a paradigm for
neurodegeneration in which a critical gene’s function depends on
its spatial and temporal context, potentially resulting in dual and
opposing effects. Our ﬁndings suggest that therapies aiming at
SNCA reduction may worsen later outcomes. These effects may not
be detected by Phase 1 clinical trials that select small samples of
early PD cases and employ short follow-up periods. Observational
studies using large and representative PD cohorts with long follow-
up periods may evaluate this critical issue.Acknowledgments
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